Johnson & Johnson buys Ollin Biosciences for $2.2 billion
Johnson & Johnson bought the Austin drug developer to grow its eye medicine business. It may pay another $1.125 billion if certain goals are met.

Johnson & Johnson announced on November 16 that it agreed to buy Ollin Biosciences, a clinical-stage drug company based in Austin, Texas. The initial price is $2.2 billion. The company may pay an additional $1.125 billion if the drug hits certain regulatory and sales goals.
Ollin Biosciences develops treatments for serious eye diseases. The deal adds an investigational drug called OLN324 to the company's pipeline. This drug targets retinal diseases like wet age-related macular degeneration.
Blackstone Life Sciences will provide $750 million to fund the final Phase 3 testing of the drug. In exchange, Blackstone Life Sciences will receive future payments and royalties. Johnson & Johnson expects to close the deal by the end of 2026.
Shares of Johnson & Johnson rose by about $2 to around $288.00 on November 16. The stock has gained 39.3% this year.
About Johnson & Johnson
U.S. multinational manufacturer of pharmaceuticals and medical devices
- Share price
- $270.47+1.25% last trading day
- Revenue
- $88.8 billiona year, 2024
- Employees
- 138,2002026
- Founded
- 1886by Robert Wood Johnson I
- Based in
- New Brunswick
- Chief executive
- Joaquin Duato
- Owned by
- ShareholdersNYSE: JNJ
From Wikipedia and Yahoo Finance. Figures can be a year or two old.
Figures as reported by ROI-NJ.



